Azimizonuzi Hannaneh, Ghayourvahdat Arman, Ahmed Mareb Hamed, Kareem Radhwan Abdul, Zrzor Athmar Jaber, Mansoor Aseel Salah, Athab Zainab H, Kalavi Shaylan
Inventor Member of International Federation of Inventors Associations, Geneva, Switzerland.
College of Dentistry, Alnoor University, Mosul, Iraq.
Cancer Cell Int. 2025 Jan 27;25(1):26. doi: 10.1186/s12935-024-03610-z.
Theranostics is a way of treating illness that blends medicine with testing. Specific characteristics should be present in the best theranostic agents for cancer: (1) the drugs should be safe and non-toxic; (2) they should be able to treat cancer selectively; and (3) they should be able to build up only in the cancerous tissue. Liposomes (LPs) are one of the most efficient drug delivery methods based on nanotechnology. Stealth LPs and commercial LPs have recently had an impact on cancer treatment. Using the valuable information from each imaging technique, along with the multimodality imaging functionality of liposomal therapeutic agents, makes them very appealing for personalized monitoring of how well therapeutic drugs are working against cancer in vivo and for predicting how well therapies will work. On the other hand, their use as nanoparticle delivery systems is currently in the research and development phase. Nanoscale delivery system innovation has made LP-nanoparticle hybrid structures very useful for combining therapeutic and imaging methods. LP-hybrid nanoparticles are better at killing cancer cells than their LP counterparts, making them excellent options for in vivo and in vitro drug delivery applications. Hybrid liposomes (HLs) could be used in the future as theranostic carriers to find and treat cancer targets. This would combine the best features of synthetic and biological drug delivery systems. Overarchingly, this article provided a comprehensive overview of the many LP types used in cancer detection, therapy, and theranostic analysis. An evaluation of the pros and cons of the many HLs types used in cancer detection and treatment has also been conducted. The study also included recent and significant research on HLs for cancer theranostic applications. We conclude by outlining the potential benefits and drawbacks of this theranostic approach to the concurrent detection and treatment of different malignancies, as well as its prospects.
治疗诊断学是一种将医学与检测相结合的疾病治疗方式。用于癌症的最佳治疗诊断试剂应具备以下特定特性：（1）药物应安全无毒；（2）它们应能够选择性地治疗癌症；（3）它们应仅在癌组织中积聚。脂质体（LPs）是基于纳米技术的最有效的药物递送方法之一。隐形脂质体和商业脂质体最近对癌症治疗产生了影响。利用来自每种成像技术的有价值信息，以及脂质体治疗剂的多模态成像功能，使其在个性化监测治疗药物在体内对抗癌症的效果以及预测治疗效果方面非常有吸引力。另一方面，它们作为纳米颗粒递送系统的应用目前正处于研发阶段。纳米级递送系统的创新使LP-纳米颗粒杂化结构对于结合治疗和成像方法非常有用。LP-杂化纳米颗粒比其脂质体对应物更擅长杀死癌细胞，使其成为体内和体外药物递送应用的极佳选择。杂化脂质体（HLs）未来可作为治疗诊断载体用于发现和治疗癌症靶点。这将结合合成和生物药物递送系统的最佳特性。总体而言，本文全面概述了用于癌症检测、治疗和治疗诊断分析的多种脂质体类型。还对用于癌症检测和治疗的多种杂化脂质体类型的优缺点进行了评估。该研究还包括关于用于癌症治疗诊断应用的杂化脂质体的近期重要研究。我们通过概述这种治疗诊断方法在同时检测和治疗不同恶性肿瘤方面的潜在益处和缺点及其前景来得出结论。
